Key result
ECMO in COVID-19 is linked to a 5-fold higher risk of bleeding vs. non-ECMO.
Why the study?
Does extracorporeal membrane oxygenation (ECMO) increase the risk of bleeding and acquired von Willebrand syndrome in mechanically ventilated critically ill COVID-19 patients compared to non-ECMO management?
Cohort (n=43)
Does extracorporeal membrane oxygenation (ECMO) increase the risk of bleeding and acquired von Willebrand syndrome in mechanically ventilated critically ill COVID-19 patients compared to non-ECMO management?
Answers are grounded in this paper and cite their sources.
In critically ill COVID-19 patients, ECMO is associated with a significantly higher risk of bleeding and the development of acquired von Willebrand syndrome compared to mechanical ventilation alone.
This study investigated the interplay between thrombosis and hemorrhage in critically ill COVID-19 patients, particularly those on extracorporeal membrane oxygenation (ECMO). Forty-three mechanically ventilated patients were divided into ECMO (n = 22) and non-ECMO (n = 21) groups. Thrombotic events occurred similarly in both groups (22.7% in ECMO, 28.6% in non-ECMO), both higher than the approximately 5% observed in patients hospitalized with viral respiratory illnesses other than COVID-19. However, bleeding events were significantly more frequent in the ECMO group (72.7%) compared to the non-ECMO group (14.3%) (P < 0.01). ECMO patients showed decreased platelet counts, fibrinogen, von Willebrand factor (VWF) activity using a ristocetin cofactor (VWF: RCo) assay, and developed acquired von Willebrand syndrome (AvWS) (VWF: RCo/VWF antigen (Ag) ratio < 0.7), along with increased D-dimer and lower high-molecular-weight VWF multimers. In contrast, the non-ECMO group showed no significant changes in platelet counts, fibrinogen, VWF: RCo, or D-dimer. Over time, both VWF: Ag and VWF: RCo increased significantly in both groups, but the VWF: RCo/VWF: Ag ratio remained above 0.7, and high-molecular-weight VWF multimers did not change significantly. These findings emphasize the need for vigilance regarding thrombotic and hemorrhagic complications, particularly in ECMO patients, where ECMO-induced shear stress may lead to AvWS, necessitating monitoring of VWF: Ag and VWF: RCo.
No takes yet. Share an insight, caveat, or question.
Ishikura et al. (2025) conducted a cohort in Critically ill COVID-19 (n=43). Extracorporeal membrane oxygenation (ECMO) vs. Non-ECMO was evaluated on Bleeding events (p=< 0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: